Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma
Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a...
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Journal article |
| اللغة: | English |
| منشور في: |
Massachusetts Medical Society
2018
|